Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug interaction study aims to prevent dangerous medication Mix-Ups

NCT ID NCT06367153

Completed Knowledge-focused Sponsor: Boehringer Ingelheim Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed phase 1 trial in 18 healthy adults examined how multiple doses of the experimental drug BI 1569912 change the way the body processes three common medications: repaglinide (for diabetes), midazolam (for sedation), and bupropion (for depression or smoking cessation). By measuring drug levels in the blood, researchers aim to understand potential interactions and guide future safe use.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
BI 1569912
What this could lead to
If successful, this study will help doctors understand how BI 1569912 interacts with other drugs, leading to safer dosing recommendations.
What could go wrong
This is a small, early-phase trial in healthy volunteers, not patients. Results may not predict effects in people with illnesses or on other medications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY

Contacts and locations

Locations

  • SGS Life Science Services - Clinical Research

    Edegem, 2650, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.